Anuh Pharma (BSE:506260) - Aandelenkoers, Nieuws & Analyse

506260 Overzicht aandelen

Anuh Pharma Limited houdt zich bezig met de productie en verkoop van bulkgeneesmiddelen en chemicaliën in India.

506260 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	5/6
Financiële gezondheid	6/6
Dividenden	4/6

Beloningen

Price-To-Earnings ratio (17x) is below the Indian market (33.3x)

Earnings grew by 42.4% over the past year

Risicoanalyse

Dividend of 1.27% is not well covered by free cash flows

Anuh Pharma Limited Concurrenten

Shree Ganesh Remedies

BSE:540737

₹10.1b

Albert David

BSE:524075

₹8.1b

Wanbury

BSE:524212

₹8.0b

Medicamen Biotech

BSE:531146

₹7.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Anuh Pharma
Historische aandelenkoersen
Huidige aandelenkoers	₹196.25
52 Week Hoogtepunt	₹265.00
52 Week Laag	₹125.00
Bèta	0.64
11 maand verandering	-3.04%
3 maanden verandering	-14.79%
1 Jaar Verandering	52.66%
33 jaar verandering	84.88%
5 jaar verandering	164.84%
Verandering sinds IPO	1,020.37%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	506260	IN Pharmaceuticals	IN Markt
7D	2.8%	2.0%	1.8%
1Y	52.7%	58.6%	36.8%

Rendement versus industrie: 506260 underperformed the Indian Pharmaceuticals industry which returned 58.6% over the past year.

Rendement versus markt: 506260 exceeded the Indian Market which returned 36.8% over the past year.

Prijsvolatiliteit

Is 506260's price volatile compared to industry and market?
506260 volatility
506260 Average Weekly Movement	5.8%
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	6.3%
10% most volatile stocks in IN Market	9.4%
10% least volatile stocks in IN Market	4.0%

Stabiele aandelenkoers: 506260 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatiliteit in de loop van de tijd: 506260's weekly volatility (6%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1960	175	Ritesh Shah	www.anuhpharma.com

Anuh Pharma Limited houdt zich bezig met de productie en verkoop van bulkgeneesmiddelen en chemicaliën in India. Het biedt actieve farmaceutische ingrediënten, waaronder macroliden, anti-TB, anti-malaria, anti-bacteriële, anti-hypertensie, slijmoplossend middel, quinolonen en tussenproducten. Het bedrijf levert ook corticosteroïden, zoals ontstekingsremmers, immunosuppressiva, anti-pruritica, anti-mitotische middelen en anti-histaminica.

Anuh Pharma Limited Samenvatting

Hoe verhouden de winst en inkomsten van Anuh Pharma zich tot de beurswaarde?
506260 fundamentele statistieken
Marktkapitalisatie	₹9.83b
Inkomsten(TTM)	₹578.14m
Inkomsten(TTM)	₹6.23b

17.0x

Koers/Winstverhouding

1.6x

P/S-verhouding

Is 506260 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
506260 resultatenrekening (TTM)
Inkomsten	₹6.23b
Kosten van inkomsten	₹4.67b
Brutowinst	₹1.56b
Overige uitgaven	₹981.64m
Inkomsten	₹578.14m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 08, 2024

Winst per aandeel (EPS)	11.54
Brutomarge	25.02%
Nettowinstmarge	9.27%
Schuld/Eigen Vermogen Verhouding	0.9%

Hoe presteerde 506260 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.3%

Huidig dividendrendement

21%

Uitbetalingsratio

506260 Overzicht aandelen

Beloningen

Risicoanalyse

Anuh Pharma Limited Concurrenten

BSE:540737

₹10.1b

BSE:524075

₹8.1b

BSE:524212

₹8.0b

BSE:531146

₹7.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Anuh Pharma Limited to Report Q2, 2025 Results on Nov 08, 2024

Insider recently sold ₹726k worth of stock

Anuh Pharma Limited Announces Cessation of Sandeep Madhusudan Joshi as Independent Director

Investor sentiment deteriorates as stock falls 18%

Upcoming dividend of ₹2.50 per share

Full year 2024 earnings released: EPS: ₹11.99 (vs ₹7.22 in FY 2023)

Recent updates

Anuh Pharma Limited to Report Q2, 2025 Results on Nov 08, 2024

Insider recently sold ₹726k worth of stock

Anuh Pharma Limited Announces Cessation of Sandeep Madhusudan Joshi as Independent Director

Investor sentiment deteriorates as stock falls 18%

Upcoming dividend of ₹2.50 per share

Full year 2024 earnings released: EPS: ₹11.99 (vs ₹7.22 in FY 2023)

Anuh Pharma Limited to Report Q1, 2025 Results on Aug 09, 2024

Anuh Pharma Limited, Annual General Meeting, Aug 23, 2024

Dividend increased to ₹2.50

Full year 2024 earnings released: EPS: ₹11.98 (vs ₹7.22 in FY 2023)

Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024

Anuh Pharma Limited to Report Fiscal Year 2024 Results on May 17, 2024

Anuh Pharma Limited Appoints Manan Jayesh Vadhan as Company Secretary and Compliance Officer

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Anuh Pharma Limited Announces Resignation of Jinal Dharmil Mehtalia as Company Secretary and Compliance Officer, Effective 14 February, 2024

Third quarter 2024 earnings released: EPS: ₹3.81 (vs ₹1.86 in 3Q 2023)

Anuh Pharma Limited to Report Q3, 2024 Results on Feb 09, 2024

Anuh Pharma Limited Announces the Resignation of Hemant Aunt as Company Secretary and Compliance Officer

Anuh Pharma Limited Announces Appointment of Ms. Jinal Ajay Shah as Company Secretary and Compliance Officer, Effective from 15 January 2024

Anuh Pharma Limited Approves the Board Appointments

Investor sentiment improves as stock rises 21%

Second quarter 2024 earnings released: EPS: ₹2.76 (vs ₹1.98 in 2Q 2023)

Anuh Pharma Limited to Report Q2, 2024 Results on Nov 10, 2023

Anuh Pharma Limited Approves Board Appointments

New minor risk - Share price stability

Anuh Pharma Limited to Report Q1, 2024 Results on Aug 11, 2023

Upcoming dividend of ₹2.00 per share at 1.5% yield

Full year 2023 earnings released: EPS: ₹7.22 (vs ₹6.10 in FY 2022)

Anuh Pharma Limited, Annual General Meeting, Aug 10, 2023

Investor sentiment improves as stock rises 25%

Full year 2023 earnings released: EPS: ₹7.22 (vs ₹6.10 in FY 2022)

Anuh Pharma Limited Announces Board Changes

Anuh Pharma Limited to Report Q4, 2023 Results on May 19, 2023

Third quarter 2023 earnings released: EPS: ₹1.86 (vs ₹1.49 in 3Q 2022)

Anuh Pharma Limited Announces Resignation of Lalitkumar P Shah as Non-Executive Director

Anuh Pharma Limited to Report Q3, 2023 Results on Feb 10, 2023

Anuh Pharma Limited Approves Appointment of Hemant Auti as the Company Secretary & Compliance Officer

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: ₹1.98 (vs ₹1.72 in 2Q 2022)

Anuh Pharma Limited Announces Resignation of Bharat Gangani as Company Secretary and Compliance Officer

Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2021-2022

Investor sentiment improved over the past week

Anuh Pharma Limited to Report Q1, 2023 Results on Aug 05, 2022

Upcoming dividend of ₹1.75 per share

Full year 2022 earnings released

Anuh Pharma Limited, Annual General Meeting, Aug 05, 2022

Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2022

Anuh Pharma Limited to Report Q4, 2022 Results on May 14, 2022

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Anuh Pharma Limited to Report Q2, 2022 Results on Feb 04, 2022

Second quarter 2022 earnings released: EPS ₹1.72 (vs ₹1.32 in 2Q 2021)

Upcoming dividend of ₹1.50 per share

Full year 2021 earnings released: EPS ₹5.68 (vs ₹2.86 in FY 2020)

Insider recently sold ₹1.3m worth of stock

Full year 2021 earnings released